Further to my previous posts on IMF, things appear to be proceeding according to plan. The Aristocrat settlement has been approved by the court. Given that this is more or less already anticipated, it is still surprising to see a surge in the share price to 80 cents briefly. The price has now stabilised at about 76 cents.
Today, a further funding agreement for a case against the Federal government has been announced concerning the Pan Pharmaceuticals affair. Given the $50m settlement with Jim Selim CEO, albeit on a without admission basis, it is difficult to see how the Federal government can avoid liability.
There is also news today of possible multiple actions by councils against Lehmann in respect of investments in CDOs and losses being suffered from the subprime crisis. This has been a pet project of IMF Hugh McLernon. I believe the chances of further funding agreements on CDO losses related matters are fairly high.
Currently, IMF is sitting on cash estimated at $80 million, which is about 66 cents per share. Market cap is 91.2 m, therefore, the business is being valued at $11.2 m for a portfolio of cases with maximum value claim of over $1 billion. The market appears to be saying that IMF will only squeeze 1% out of its portfolio.
This is still within Ben Graham region, with no regard to a defensive business in a monopolistic position in a growing market.
As per previous post, watch out for court judgments.